Clinical Development Intelligence
Investigational Prophylactic Pipeline · Trial Feasibility
Live ClinicalTrials.gov snapshot of the sponsor's flu franchise and the competitive landscape. Filter by phase, condition, or sponsor to plan protocol design and site selection.
Data source
This view integrates with ClinicalTrials.gov — showing Investigational Prophylactic protocols (Phase 3 pivotal Phase 3, Phase 2b readout Phase 2b) alongside the competitive influenza pipeline.
Phase 3 pivotal Phase 3 N
~6,000
High-risk participants
Sites
~150
US + UK
Phase 2b readout VE
76%
Phase 2b readout
Anticipated launch
2028
FDA Breakthrough + Fast Track
Active influenza prophylaxis trials
Cross-sponsor flu franchise pipeline